Lyndon serves as the President and Chief Executive Officer and member of the Board of Directors and provides overall leadership for the company. Previously, Lyndon was Vice President of Corporate Strategy and Alliances at Elan Pharmaceuticals and was responsible for strategic planning, product planning and business development. As Director of Technology Planning at ALZA, a specialty pharmaceutical company of Johnson & Johnson, he led technology strategy and guided new product planning teams. He was a Principal at the venture capital company Coastview Capital and led and supported successful investments in early stage biopharmaceutical and research tool companies. He was also a management consultant at McKinsey & Company and a leader in the Pharmaceutical and Medical Products Practice. He provided direction to senior executives of leading healthcare companies on business strategy, R&D; strategy, operations, new business creation, mergers/acquisitions, and product commercialization.

Lyndon has an A.B. in Biochemical Sciences from Harvard University, an M.B.A. from MIT Sloan School of Management and a Ph.D. in Genetics from Harvard University.

Patricia serves as the Chief Medical Officer and leads clinical development and drug safety for the company. Previously, she was Senior Health Administrator and Medical Officer at the National Institute of Neurological Disorders and Stroke where she led formation of a trans-federal clinical trial network and contributed to clinical trial networks and new initiatives in the Offices of Clinical Research and Translational Research. She was a clinical research consultant for multiple biotechnology companies including Balance Therapeutics where she led clinical development for the Down syndrome program. She was the Chief Medical Officer at OXiGENE and oversaw clinical development and operations for programs in oncology. Prior to that, she was Vice President of Clinical and Regulatory at Avidia and led translational research and clinical development of avimers, a novel protein therapeutic platform. She was Vice President of Clinical Development at Rinat Neuroscience and Medical Director at Genentech and Elan. She was also an Adjunct Professor at USCF, Mercer University, Emory and the Salk Institute.

Patricia has a B.S in biology from the Massachusetts Institute of Technology and a M.D-Ph.D. from Harvard University. Dr. Walicke completed her residency in neurology at McGill University and University of California, San Diego.

Herb serves as the Chief Financial Officer and leads finance, investor relations, information technology and all other administrative functions for the company. Previously, Herb was Chief Financial Officer and interim Chief Executive Officer at KaloBios Pharmaceuticals and was responsible for providing overall strategic leadership for the company in addition to leading the finance and administrative functions. As Chief Financial Officer at Affymax, he was a key spokesperson for the company to the public markets in addition to being responsible for finance, information technology and facilities across the company. Prior to that, Herb served as Vice President, Finance for Facet Biotech Corporation, a spin-off of PDL BioPharma where he was Executive Director, Finance and Corporate Controller. In both roles, Herb had responsibility for financial operations and strategy across all aspects of the company including research, development, manufacturing and commercial operations. He also served as Vice President, Finance, at Neoforma, Inc., a public e-commerce software company early in his career.

Herb has a B.S. from the Haas School of Business at the University of California, Berkeley and is a certified public accountant, currently inactive, in the state of California.